We report a 73-year-old woman under post-surgical chemotherapy (breast ductal carcinoma) who presented with transudation and pain on the lower limbs 20 days after the first cycle with doxorubicin and cyclophosphamide and no improvement with furosemide.
CASE REPORT
We report a 73-year-old woman under post-surgical chemotherapy (breast ductal carcinoma) who presented with transudation and pain on the lower limbs 20 days after the first cycle with doxorubicin and cyclophosphamide and no improvement with furosemide.
Due to treatment failure after four cycles of adjuvant regimen, the patient was started on herceptin and paclitaxel. From the 45 th day of this new regimen, we observed the development of an edema and considerable erythema on the hands, wrists, legs, and feet.
We also observed desquamation, ulceration, vesicopustules, and intense burning sensation. Little improvement was observed after analgesia, topical corticosteroids and cephalexin (Figures 1 and 2 ).
Laboratory tests were normal. Histopathological examination showed areas of epidermal necrosis with small clefts, keratinocyte apoptosis, parakeratosis foci, and basal vacuolar degeneration with extensive involvement of the acrosyringium without squamous syringometaplasia.
We opted for hospitalization, suspension of chemotherapy, and administration of opioids, prednisone (0.5 mg/kg), potassium permanganate compresses, and application of occlusive dressing with fludroxycortide. The patient was discharged five days later with significant improvement in pain and lesions. After alopecia and mucositis, HFS is the most common adverse dermatologic reaction to chemotherapy, with an incidence of 3%-64%. The highest incidences occur with doxorubicin (40%-50%) and capecitabine (50%-60%). The risk of HFS seems to be dose-dependent: formulations that prolong the serum level or that concentrate the drug at the affected sites have the highest association rates. 1 The pathogenesis of HFS is not known. It is believed to be a toxic reaction due to the local accumulation of the drug with consequent degeneration and necrosis of the sweat glands. That is because its microscopic features resemble squamous eccrine syringometaplasia and neutrophilic eccrine hidradenitis patterns. With an aging population and greater access to health care and oncological diagnosis, cutaneous reactions to chemotherapy should become more frequent. Prevention, identification, and early intervention is essential for clinicians in cases of HFS.q Abstract: Hand-foot syndrome is a common cutaneous adverse effect associated with certain systemic chemotherapy drugs. It is characterized by erythema, edema, and burning sensation, especially over palmoplantar surfaces. We report the case of an elderly patient undergoing chemotherapy after a breast cancer surgery who developed symptoms two months after the start of the regimen. There are no studies that explore specific therapies. Suggestive therapy include reducing agent dosage, increasing the interval between cycles, or even stopping chemotherapy. Emollients, analgesics, and cold packs are described as effective. After alopecia and mucositis, hand-foot syndrome is the most common adverse dermatologic reaction to chemotherapeutic agents. Keywords: Adjuvant chemotherapy; Chemotherapy; Drug eruption; Hand-foot syndrome 
